Thirona’s RetCAD™ and iCare are joining forces in AI eye care solutions


Thirona’s RetCAD™ and iCare are joining forces in AI eye care solutions


Published On: April 28th, 2022
Nijmegen, the Netherlands (April 27th, 2022) – Thirona, one of the leading companies specializing in artificial intelligence for medical image analysis, has signed a strategic partnership agreement with iCare, for the implementation of Thirona’s RetCAD™ artificial intelligence software into the iCare solutions for eye disease screening, in Europe. The partnership underpins both companies’ technological leadership in this field.

 

iCare is part of Revenio, a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. Icare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for diagnosis of glaucoma, diabetic retinopathy, and age-related macular degeneration (AMD).

”This is an exciting opportunity to contribute to keeping the wonderful world visible for all. Together with Thirona, we are implementing a top-performance screening solution based on fundus images. We start by screening diabetic retinopathy from diabetics and bring to market an integrated service that is fast and easy to use thanks to automation. High-quality images from the iCare DRSplus fundus imaging system provide a good foundation for the solution” says Pirjo Kortteisto, business development manager of Icare Finland.

Having every patient fundus examination instantly analyzed with a clinically validated software system, initial screening procedures can be done more efficiently and at least as accurate as when conducted by human experts. Simplified visualization of the examination analysis with heat maps supports eye care providers in validating the AI results and helps improve patient engagement in the prevention of severe eyesight problems and blindness.

“Combining high quality of iCare’s fundus images with RetCAD’s reliability of automated analysis, together we can provide eye care practitioners with a powerful trustworthy solution, enabling them screening more patients faster. Seamless integration of RetCAD™ into the iCare platform enables an optimal user experience, with test results instantly presented in a form of simple visualization, meaningful for the patient”, says Mark van Grinsven, head of Retina division at Thirona.

RetCAD™ is already distributed worldwide through integration partnerships with major fundus camera vendors such as Topcon, Canon, Tomey and Nidek, as well as medical solutions providers such as Delft Imaging. “By joining forces with iCare we can bring innovation to the mainstream markets faster. iCare is not just a distribution channel for us. Partnerships based on a shared vision and mutual trust are very centric to Thirona’s strategy, so we are happy to have iCare as our strategic partner”, says Diederik Sakkers, business development manager RetCAD at Thirona.

xxx

About Thirona

Thirona is an innovative company specializing in artificial intelligence for medical image analysis that allow for precise quantification of disease symptoms and contribute to personalized patient treatment. Thirona partners with research institutions and medical companies in their innovation trajectories aimed to enable breakthroughs in treatment development and clinical care. Founded in 2014 by female scientist Eva van Rikxoort, the company develops highly innovative deep learning solutions for lung and retinal image analysis. Rooted in science and providing reliable and user-friendly solutions, it bridges the gap between academic ideas and clinical use. Since inception in 2014, Thirona has become an important player in the medical imaging field.

RetCAD™, one of Thirona’s brands, is a MDR class IIa certified software using artificial intelligence that analyses color fundus images for the presence of eye diseases. It assists eye care providers in early diagnosis and grading of the vision threatening diseases. RetCAD™ uses state-of-the-art deep learning and computer vision technology, utilizing large amounts of human-specialist graded images, to provide quantified clinical outcome measures.

For more information visit: retcad.thirona.eu

Media contact: mediarelations@thirona.eu

About Revenio Group

Revenio is a leading company in the global market for ophthalmological devices and software solutions. Revenio’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), fundus imaging devices, and perimeters as well as clinical software under the iCare brand. iCare is a trusted partner in ophthalmic diagnostics, offering physicians fast, easy-to-use, and reliable tools for the diagnosis of glaucoma, diabetic retinopathy, and macular degeneration (AMD). iCare Solutions provide digital clinical tools that drive greater efficiency and enhance quality in eye care.

In 2021, the Group’s net sales totaled EUR 78.8 million, with an operating profit of EUR 22.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

For more information visit: www.revenio.fi

Media contact: pirjo.kortteisto@revenio.fi

Share This Story, Choose Your Platform!